Print

Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against traveller’s diarrhoea

2000-08-08

Active Biotech has taken back the worldwide rights for the ETEC vaccine project. The ongoing phase III clinical trials in Mexico and Guatemala are continuing according to plan. Alternative partnering strategies are under evaluation as well as the future clinical trials program.

Furthermore, all the international marketing rights for the SBL Cholera Vaccine have been transferred back to Active Biotech.

As part of the agreement, SmithKline Beecham’s (SB) paediatric vaccines, currently sold by Active Biotech through SBL Vaccin under an agreement that were to expire 2003, will be transferred to the Nordic organisation of SB from 1 January 2001.

In line with Active Biotechs´s strategy to focus on vaccines for travellers, Active will receive a license for Sweden from SB regarding a second brand of their product HAVRIX, a vaccine to prevent hepatitis A infections. This product will be marketed by Active Biotech´s Swedish marketing organisation SBL Vaccin.

These changes are not estimated to have any effect on the result of Active Biotech for the years 2000 –2001.

Lund 8 August 2000

pdf



Back